Fate Therapeutics (FATE) Misses Q4 EPS by 1c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Fate Therapeutics (FATE) Misses Q4 EPS by 1c, Revenues Miss

Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

March 5, 2019 4:01 PM EST

First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial

Marks First-ever Human Administration of iPSC-derived Cell Therapy in the United States

$201 Million in Cash & Short-term Investments as of December 31, 2018

SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2018.

We achieved an... More